Oppenheimer Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $350

Benzinga · 3d ago
Oppenheimer analyst Kostas Biliouris maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $500 to $350.